Evidence map›Paper›PMID 26485480›Full record

ArticleJournal of addictive diseases2016

Substance use history in behavioral-variant frontotemporal dementia versus primary progressive aphasia.

Raj K Kalapatapu, Kevin L Delucchi, Sophia Wang, John D Harbison, Emily E Nelson, Joel H Kramer

Abstract read
In one paragraph

Article in Journal of addictive diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Raj K Kalapatapua Department of Psychiatry , University of California , San Francisco , California , USA.
Kevin L Delucchia Department of Psychiatry , University of California , San Francisco , California , USA.
Sophia Wangd Department of Psychiatry , Indiana University, Center for Health Innovation and Implementation Science , Indianapolis , Indiana , USA.
John D Harbisona Department of Psychiatry , University of California , San Francisco , California , USA.
Emily E Nelsona Department of Psychiatry , University of California , San Francisco , California , USA.
Joel H Kramere Memory and Aging Center , Department of Neurology, University of California , San Francisco , California , USA.
University of California, San Francisco · USSan Francisco VA Medical Center · USIndiana University – Purdue University Indianapolis · US

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
TREATMENTS FOR COMPLEX PATIENTS IN NEW SETTINGSP50DA009253 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MEYERHOFF, DIETER J · 1994 to 2014
$28.2M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
Decision-Making in Genetic FTDR01AG022983 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIONG, WINSTON · 2004 to 2021
$6.0M
OT-based Cognitive Rehabilitation of Cocaine AbusersK23DA034883 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KALAPATAPU, RAJKUMAR KIRAN · 2013 to 2017
$900k
NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NIA NIH HHS P50AG023501NIA NIH HHS R01 AG022983NIA NIH HHS R01AG022983NIA NIH HHS R01 AG032289NIA NIH HHS R01AG032289NIA NIH HHS U01 AG016976NIA NIH HHS UO1 AG016976NIDA NIH HHS K23 DA034883NIDA NIH HHS K23DA034883NIDA NIH HHS P50 DA009253NIDA NIH HHS P50DA009253
6 · The paper itself

Abstract

As older adults are prone to cognitive disorders, the interaction of the fields of substance use and misuse and cognitive neuroscience is an emerging area of research. Substance use has been reported in some subtypes of frontotemporal dementia, such as behavioral variant frontotemporal dementia. However, characterization of substance use in other subtypes of frontotemporal dementia, such as primary progressive aphasia, is unknown. The objective of this baseline analysis was to explore whether any measures of substance use history differed significantly among behavioral variant frontotemporal dementia (n = 842) and primary progressive aphasia (n = 526) in a large national dataset. The National Alzheimer's Coordinating Center's Uniform Data Set study is a national dataset that collects data on patients with various cognitive disorders and includes some questions on substance use. Each substance use variable was used as the outcome and the frontotemporal dementia subtype as the predictor. Total years smoked cigarettes, age when last smoked cigarettes, average number of packs/day smoked when participants smoked, and any recent, remote, or combined recent/remote history of alcohol abuse or drug abuse did not significantly differ between the behavioral variant frontotemporal dementia and primary progressive aphasia subtypes (all p-values > .001). A significantly greater percentage of participants smoked in the last 30 days in the behavioral variant frontotemporal dementia subtype (10.4%, n = 834) compared to the primary progressive aphasia subtype (3.3%, n = 517; p < .001). Clinical providers in both the dementia and substance use fields are encouraged to screen for and monitor substance use in all frontotemporal dementia subtypes.

Indexed as

AgedAlcohol DrinkingAphasia, Primary ProgressiveFemaleFrontotemporal DementiaHumansMaleMiddle AgedRisk FactorsSmokingSubstance-Related DisordersUnited Statesalcoholcigarette smokingdementiadrugFrontotemporalsubstance use

Identifiers

PMID26485480
PMCPMC4720534
OpenAlexW1762022138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.